Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
3 Monster Stocks to Hold for the Next 10 Years
11:08am, Saturday, 07'th Dec 2024
It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story.
Is Iovance Biotherapeutics Stock a Millionaire Maker?
06:30am, Wednesday, 27'th Nov 2024
The biotech industry has been described as the Wild West of the stock market. Although some companies manage to develop and commercialize a life-changing therapeutic, countless more start-ups inevitab
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
04:01pm, Tuesday, 26'th Nov 2024
SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
11:35am, Saturday, 23'rd Nov 2024
As the rising star of cell therapy biotechs, Iovance Biotherapeutics (IOVA 3.76%) is a hot stock that's capturing a lot of attention, and for good reason. Iovance's one-of-a-kind medicine is already s
2 Innovative Stocks That Could Deliver Outsize Returns
10:00am, Friday, 22'nd Nov 2024
2 Innovative Stocks That Could Deliver Outsize Returns
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
06:00am, Saturday, 16'th Nov 2024
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
02:16pm, Monday, 11'th Nov 2024
Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows st
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
11:15am, Friday, 08'th Nov 2024
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
08:55pm, Thursday, 07'th Nov 2024
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
06:46pm, Thursday, 07'th Nov 2024
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
04:01pm, Thursday, 07'th Nov 2024
Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Mark
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Why Iovance Biotherapeutics Stock Triumphed on Thursday
06:01pm, Thursday, 24'th Oct 2024
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
Is Iovance Biotherapeutics Stock a Buy?
08:30am, Friday, 04'th Oct 2024
The biotech is making important breakthroughs, but is that enough?
Iovance Biotherapeutics: Moving To The Next Phase
02:43pm, Thursday, 03'rd Oct 2024
Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects ar
